Showing 1881-1890 of 2652 results for "".
- Silicon Valley Eye Doctor Named Optometrist of the Year By American Optometric Associationhttps://modernod.com/news/silicon-valley-eye-doctor-named-optometrist-of-the-year-by-american-optometric-association/2480071/The California Optometric Association (COA) announced that David M. Redman, OD, has been named the “Optometrist of the Year” for 2017 by the American Optometric Association (AOA). Dr. Redman is a practicing optometrist and partner in Precision Eyecare Centers in San Jose and Mountain View. Dr. Re
- Ophthalmic OR Microscope Market to See More Than 6 Percent Growth over Next Five Yearshttps://modernod.com/news/ophthalmic-or-microscope-market-to-see-more-than-6-percent-growth-over-next-five-years/2480110/Market Scope expects the global ophthalmic operating room (OR) microscope market to grow at a healthy pace of more than 6 percent over the next 5 years, as 2018 revenues of $403 million climb to nearly $548 million by 2023. Revenues will rise most sharply in Latin America and other develop
- EyePoint Pharmaceuticals’ Yutiq for Posterior Segment Uveitis to be Presented at the 2018 ARVO Annual Meetinghttps://modernod.com/news/eyepoint-pharmaceuticals-yutiq-for-posterior-segment-uveitis-to-be-presented-at-the-2018-arvo-annual-meeting/2480232/EyePoint Pharmaceuticals announced that two abstracts supporting the company’s Yutiq (fluocinolone acetonide intravitreal implant) 0.18 mg 3-year micro-insert for noninfectious posterior segment uveitis have been accepted for presentation at the Association for Research in Vision and Ophtha
- SIFI Announces Approval of Mini Well Ready IOL in Singaporehttps://modernod.com/news/sifi-announces-approval-of-mini-well-ready-iol-in-singapore/2480263/Italian ophthalmic company SIFI has announced the approval of the Mini Well Ready IOL by Singapore’s Health Science’s Authority. Mini Well Ready is an innovative, aspherical, EDOF, progressive IOL designed for the surgical correction of presbyopia. “It is today increasingly rec
- Oculis Begins Phase 2b RELIEF Trial of Topical Anti-TNFα Licaminlimab (OCS-02) in Dry Eye Diseasehttps://modernod.com/news/oculis-begins-phase-2b-relief-trial-of-topical-anti-tnfa-licaminlimab-ocs-02-in-dry-eye-disease/2481998/Oculis announced 'First Patient First Visit' (FPFV) in its phase 2b RELIEF trial evaluating the potential of licaminlimab (also known as OCS-02), Oculis’ anti-TNFα biologic eye drop drug candidate for the treatment of dry eye disease (DED). The phase 2b REL
- EyeMed Vision Care, Vision Council Foundation Expand Partnership for Second Yearhttps://modernod.com/news/eyemed-vision-care-vision-council-foundation-expand-partnership-for-second-year/2486331/Key Takeaways
- Sight Sciences Announces Fee Schedule Establishment for TearCare Dry Eye Procedurehttps://modernod.com/news/sight-sciences-announces-fee-schedule-establishment-for-tearcare-dry-eye-procedure/2484193/Sight Sciences announced that two Medicare Administrative Contractors (MACs), Novitas Solutions and First Coast Service Options (FCSO), each established jurisdiction-wide pricing for CPT code 0563T (evacuation of meibomian glands, using heat delivered through wearable, open-eye eye
- Valitor Presents Preclinical Datasets on the Potential of its Anti-VEGF Therapy Dosed Twice Yearly for Wet AMDhttps://modernod.com/news/valitor-presents-preclinical-datasets-on-the-potential-of-its-anti-vegf-therapy-dosed-twice-yearly-for-wet-amd/2482790/Valitor announced data from VLTR-559, its long-acting anti-VEGF biologic in development for its wet age-related macular degeneration (AMD) treatment, and its multivalent polymer (MVP) technology platform, were presented at the 2025 Association for Research in Vision and Ophthalmology (ARVO) annua
- Nicox Announces First Commercial Sale of Zerviate in China by Partner Ocumensionhttps://modernod.com/news/nicox-announces-first-commercial-sale-of-zerviate-in-china-by-partner-ocumension/2482566/Nicox announced the first commercial sale of Zerviate (cetirizine ophthalmic solution), 0.24% in China by its exclusive Chinese partner Ocumension yesterday – a significant milestone in their longstanding collaboration since 2018. Zerviate is indicated for ocular itchin
- False Claims Act Complaint Filed Against Regeneron for Fraudulent Drug Pricing Reportinghttps://modernod.com/news/false-claims-act-complaint-filed-against-regeneron-for-fraudulent-drug-pricing-reporting/2482228/The US Department of Justice (DOJ) has filed a complaint under the False Claims Act (FCA) against Regeneron alleging that the company fraudulently inflated Medicare reimbursement rates for Eylea (aflibercept) by knowingly submitting false average sales price reports to CMS that excluded